American Shared Hospital Services (AMS) Earnings Call Transcript & Summary
November 12, 2026
Earnings Call Speaker Segments
Kirin Smith
executiveThanks, Gary, and thanks to all of you for being with us today. Earlier today we issued AMS's Third Quarter 2026 Earnings Press Release. Should you need a copy, you can find it on the company website at www.ashs.com in the Investors section. Before I hand the call over to management, I want to make a few remarks about forward-looking statements. Please be aware that any remarks made on this conference call regarding future expectations, plans, and prospects for the company are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those indicated by these forward-looking statements because of various important factors, including those discussed in the company's filings with the SEC, including the company's annual report and Form 10-K for the year ended December 31, 2025, and Form 10-Qs for the quarters ended June 30, 2026, and March 31, 2026. The company undertakes no obligation to update the information contained in this conference call. Before I turn the call over to management, I'd like to remind everyone about our Q&A policy, under which we give each participant time to ask one question and one follow-up. As always, we're happy to take additional questions offline. With that, I'd now like to turn the call over to Ray Stachowiak, Executive Chairman. Ray, please go ahead.
Ray Stachowiak
executiveThanks, Kirin, and thanks to all of you for being with us today. I'll start by giving an update on where we stand with our strategic priorities, and then I'll share some perspective on how the company is performing operationally, on our growth opportunities, and on our financial position. Through the first nine months of fiscal 2026, we keep making headway in growing our Direct Patient Services business, all while maintaining the Medical Equipment Leasing operations we've long had in place. Total revenue rose roughly 14% compared with a year earlier, and revenue from Direct Patient Services was up approximately 27%. That growth reflects the ongoing contribution from our Rhode Island operations as well as from our international facilities. Our strategy is still centered on building a business that is stronger and more diversified, with a heavier emphasis on Direct Patient Services. We think this approach opens up opportunities to take part more directly in delivering specialized radiation therapy services, while drawing on our experience and our long-standing relationships within the medical technology industry. We keep seeing opportunities across the operations we already have. Our Gamma Knife facilities in Peru and Ecuador have helped drive growth in patient procedures, and our Rhode Island operations remain an important piece of our Direct Patient Services platform; we're also continuing to move our international development initiatives forward. One opportunity of real importance is the joint venture we have with Hospital San Javier in Guadalajara, Mexico. As things stand, we expect that facility to start treating patients in mid-2027. We believe this project gives us a chance to broaden our presence in a market that matters and to build on the experience we've gained running specialized radiation therapy facilities. At the same time, we're still focused on our capital structure and are evaluating alternatives. We've been working with our lenders and other stakeholders to address these matters. The financing arrangements we have now call for continued attention and for execution against specified milestones, and our focus is on navigating through them while we enhance the value of our operating businesses and pursue opportunities for long-term growth. As we discussed on our last call, several months ago I formed a new company that bought additional shares from a private investor. On top of that, this new company put $2 million of subordinated finance in during the past quarter, which shows my continued confidence in the overall company and gives us additional financial flexibility as we move forward. Clearly, we have valuable assets, experienced personnel, and meaningful opportunities to expand our Direct Patient Services platform. Our priority is turning those strengths into sustainable operating performance and better financial results. I'm still excited about our future prospects and the growth opportunities ahead, and my commitment to enhancing shareholder value is as strong as it has ever been; with that, I'll hand the call over to Craig Tagawa, our Interim Chief Executive Officer, who will go into greater detail on the company's operating performance and business developments. Craig?
Craig Tagawa
executiveThanks, Ray, and thanks to all of you for being with us today. As Ray said, we kept making headway in expanding our Direct Patient Services business over the first nine months of fiscal 2026. In the third quarter, total revenue rose 6.3% to roughly $7.6 million, versus roughly $7.2 million in the same period a year earlier; across the first nine months, revenue grew 13.7% to roughly $23.1 million, versus roughly $20.4 million last year. Our Direct Patient Services segment was the main force behind that growth. Segment revenue for the third quarter climbed about 14% to $4.6 million, and nine-month revenue climbed 27% to $13.5 million. Our Direct Patient Services operations take in our radiation therapy facilities in Rhode Island and Puebla, Mexico, along with our Gamma Knife facilities in Peru and Ecuador. Our international Gamma Knife operations keep delivering solid results. Total Gamma Knife procedures rose about 11% in both the third quarter and the first nine months versus the prior year periods. In Peru, upgrading to the Leksell Gamma Knife Esprit system has helped improve treatment efficiency, which has led to shorter treatment times. We think this investment has strengthened the facility's capacity to serve patients and to support growth in the future. In Rhode Island, our radiation therapy operations stay an important piece of the Direct Patient Services business. Revenue from the Rhode Island and Puebla radiation therapy facilities rose in both the third quarter and the nine-month periods. Even though procedure volumes at these facilities came in somewhat lower than in the prior year periods, revenue went up, which reflects the overall contribution these operations make to the segment. Our Proton Beam Radiation Therapy system also remains an important part of our business. Revenue from the PBRT system was lower in the third quarter than in the prior year period, even though revenue for the first nine months went up. Procedure volumes can swing from quarter to quarter depending on treatment scheduling and other factors, and we stay focused on supporting utilization of this specialized asset. Our Medical Equipment Leasing segment brought in roughly $3 million of third quarter revenue and $9.6 million for the first nine months. Although revenue came in modestly lower than in the prior year periods, the segment keeps providing an established base of recurring revenue from our equipment leasing relationships. On operations, our priorities stay centered on improving utilization at our facilities, supporting clinical and administrative teams, strengthening referral relationships, and improving revenue cycle execution. We are also still assessing opportunities to improve operating efficiency and to manage costs throughout the organization. We understand that reimbursement levels, procedure volumes, staffing, maintenance costs, and local market conditions can all affect the financial performance of our Direct Patient Services facilities. We stay focused on managing these factors while we keep building the platform for growth in the future. Looking forward, we believe our Direct Patient Services operations offer an important opportunity to broaden our participation in specialized radiation therapy markets. Our attention will stay on running operations well, investing sensibly, and making the financial results of the facilities we already have better. At this point I'll hand things over to Alexis Wallace, Interim Chief Financial Officer and Chief Accounting Officer, so she can walk through the financial results in greater detail.
Alexis Wallace
executiveThanks, Craig, and hello everyone. I'll begin by going over the financial results for the third quarter and the first nine months of fiscal 2026, after which I'll discuss our balance sheet and liquidity. For the third quarter, which ended September 30, 2026, total revenue came in at roughly $7.6 million, up from about $7.2 million in the same quarter a year earlier — a gain of roughly $453,000, or 6.3%. Revenue in our Direct Patient Services segment rose by about $549,000, or 13.6%, reaching $4.6 million. That growth came mainly from stronger revenue at our Rhode Island radiation therapy facilities and from our international Gamma Knife operations. Our Medical Equipment Leasing segment generated approximately $3 million, versus roughly $3.1 million in the prior year quarter. Gross profit for the quarter was about $1.5 million, compared with approximately $1.6 million a year earlier. Gross margin came to 19.9%, down from 22.1%. Selling and administrative expenses rose to roughly $1.8 million from about $1.5 million in the prior year quarter. That increase stemmed primarily from legal, banking, and consulting costs tied to activities involving our credit agreement and capital structure strategies. Other direct operating costs also climbed, largely reflecting the cost structure of our Direct Patient Services operations as well as a higher allowance for credit losses connected with the Rhode Island facilities. Depreciation and amortization expense fell versus the prior year period, mainly because of the expiration of a customer lease and certain Rhode Island assets becoming fully depreciated. Net loss attributable to American Shared Hospital Services for the third quarter was approximately $620,000, or $0.09 per diluted share, versus a net loss of roughly $17,000 in the prior year quarter. EBITDA for the third quarter of 2026 was about $1.4 million, compared with approximately $1.9 million in the prior year quarter. I'll now go through the nine-month results. Total revenue for the first nine months of 2026 grew by roughly $2.8 million, or 13.7%, to $23.1 million, compared with $20.3 million a year earlier. Direct Patient Services revenue rose by about $2.9 million, or 27%, to $13.5 million. Medical Equipment Leasing revenue was approximately $9.6 million, compared with $9.7 million in the prior year period. Gross profit for the first nine months was about $4.2 million, compared with approximately $4.1 million a year earlier. Gross margin was 18.3%, versus 20.4%. Selling and administrative expenses increased to roughly $5.8 million from about $5.1 million in the prior year period. As was the case in the third quarter, that rise mainly reflected higher legal, banking, and consulting costs related to our credit agreement and associated matters. Other direct operating costs were up compared with the prior year period, reflecting the operating cost structure of the Direct Patient Services segment and the higher allowance for credit losses connected with the Rhode Island facilities. Interest expense came in at roughly $1.1 million, down from about $1.3 million in the same period a year earlier, largely because the average outstanding principal balance was lower; across the first nine months, the net loss attributable to American Shared Hospital Services stood at about $1.7 million, or $0.26 per diluted share, versus a net loss of roughly $922,000, or $0.14 per diluted share, in the prior year period. EBITDA for the first nine months of fiscal 2026 totaled approximately $3.8 million, compared with about $4.6 million in the prior year period. Now on the balance sheet, cash equivalents and restricted cash rose to roughly $9.5 million as of September 30, 2026, up from about $3.7 million at December 31, 2025. Over the first nine months of fiscal 2026, operations generated approximately $5.8 million in cash. The working capital deficit was about $4.6 million at September 30, 2026, versus a deficit of roughly $5.7 million at December 31, 2025. The current portion of long-term debt, net, fell to approximately $15.6 million at September 30, 2026, from about $17.3 million at December 31, 2025. As we disclosed earlier, this past July the company signed an amendment and forbearance agreement with Fifth Third Bank, through which the lender agreed to refrain from exercising certain rights and remedies until June 30, 2027. We are continuing to assess our alternatives and to engage with our lenders and other stakeholders in order to address these matters and weigh potential alternatives. We will keep providing updates as appropriate. As we look ahead, our priorities are unchanged. We stay focused on driving continued revenue growth and boosting utilization throughout our existing network while growing our installed base of advanced radiation therapy technologies. Importantly, we are laser-focused on turning that revenue growth into better profitability and operating cash flow; and just as critical, we have strategies in place to further strengthen our balance sheet and capital structure while preserving the flexibility needed to support future growth opportunities and create long-term shareholder value. All in all, we are pleased with the progress we have made this year. The fundamentals of our business keep improving. Our operating cash flow remains strong. Demand across our treatment platform is healthy, and we believe the company is well-positioned to build on this momentum for the rest of the year. That wraps up my review of the financial results. I will now hand the call back to Craig to begin the question. Excuse me. I will turn the call back to Gary, the operator, to begin the question-and-answer session.
Pam Marron
analystThanks. As you work on refining the capital structure while continuing your growth efforts, I think you've said in the past that you would pursue an asset-light model for some growth projects, and I believe two of those projects are under development in Rhode Island. Is it premature to assume that no talks have taken place with potential investment partners regarding either of those, or in fact any of the other projects in your pipeline? Thanks.
Ray Stachowiak
executiveThanks, Pam. Ray Stachowiak here, Executive Chairman. Appreciate your question, Pam; we continue to make headway on our Rhode Island opportunities. We have signed a CON for a linear accelerator in Bristol, Rhode Island, as well as one for delivering a Proton Beam Radiation Therapy system in Johnston, Rhode Island. Both of those projects are progressing. At the moment we're in the design stage on them. I'd say not a great deal of CapEx has been spent so far, though substantial work is underway. In fact, we have a project sitting in backlog rather than pipeline with Hospital San Javier in Guadalajara, Mexico, to supply a Gamma Knife — an upgraded Gamma Knife at their facility — and it will rank as one of just three Gamma Knives in Mexico. That project is moving ahead, and we anticipate it being operational in mid-2027.
Pam Marron
analystThanks.
Ray Stachowiak
executivePardon me — it's on our Proton Beam Radiation Therapy system project that we're following the asset-light approach.
Pam Marron
analystUnderstood. Thanks. All right, and here's my follow-up. I believe you had signaled that it was reasonable to expect some gross margin erosion as the product mix continues shifting increasingly toward the Direct Patient Services revenue line, which I think makes sense. When you discuss aiming to increase operating profitability and make your operations more efficient, how much of expanding margins at the gross margin level do you believe is within the company's control? And then clearly, at the operating margin level, I would imagine there is certainly more control. Thank you.
Ray Stachowiak
executiveAt the gross margin level, we keep pursuing operating efficiencies, and we believe there is still room to improve those margins. At the operating level, we are bearing an inordinate amount of costs related to our banking relationship, legal fees tied to that, consulting fees, and so forth, which is weighing down our profitability at this point in our evolution. Once those costs disappear and we resolve our relationship with Fifth Third, our operating margin levels should improve.
Pam Marron
analystThanks.
Tony Kamin
analystHello. Ray, can you address the current situation in Rhode Island? You've been on this track from the moment you acquired the Rhode Island operations, working to optimize what were likely businesses that hadn't been managed particularly well. Would you characterize it as 50% done, 75% done? Where would you place it? And on that note, when you bring up new growth opportunities, it appears that if you've made enough progress optimizing the existing operations, then in considering new growth opportunities, are there any beyond the ones you've mentioned during today's call—areas where you have a potential pipeline that might extend past what you've already covered?
Ray Stachowiak
executiveUh-huh. Tony, thanks so much for that question — I appreciate it, and it's always nice to hear from you. Our view hasn't changed: there are operational efficiencies we can capture in Rhode Island. Revenues and procedure volumes have both been climbing, yet we aren't seeing quite the payoff we'd anticipate. At times it feels like we move two steps ahead and then slip one back. Still, we're quite optimistic about what's possible at our current Rhode Island facilities, as well as the two additional ones in the pipeline for which we hold the CONs. There are additional prospects in our pipeline as well, though we're holding back on pushing those harder until the situation with our lenders—specifically Fifth Third Bank—gets worked out.
Tony Kamin
analystAll right. My follow-up question was exactly about that. It's good to see the cash balance has risen to, I believe, $9.5 million, compared with $15 million of short-term debt currently due. Yet if you look at roughly the net difference between the two against your EBITDA, your ratios really aren't all that poor. I suppose, could you give us a bit more of a sense of- Do you see it that way? And are you finding any kinds of paths toward moving past what clearly was a very tough situation, which, with your cash pile growing, appears to be lightening that burden somewhat?
Ray Stachowiak
executiveYes. Thank you. The picture I'd like to paint, I think, is that we've signed a forbearance agreement with Fifth Third Bank, which is our main lender. At the end of September, we owed them approximately $15 million. As you can see, we hold $9.5 million in cash against a $15 million indebtedness to Fifth Third, and we should be able to find a solution to that. Beyond that, we produced $5.8 million of cash from operations during the first nine months of this year; so those are the metrics that, in a way, guide me and leave me feeling very confident about our future.
Tony Kamin
analystYeah. It really looks like things are getting better. In any case, many thanks.
Craig Tagawa
executiveThanks to all of you for being with us today and for the ongoing interest you show in American Shared Hospital Services. Over the first nine months of fiscal 2026, we kept expanding our Direct Patient Services business and moved forward with building out our specialized radiation therapy platform. Our attention stays on lifting operating performance, raising utilization throughout our facilities, controlling costs, and dealing with our financing arrangements. We know that significant financial and operational opportunities lie ahead of us. Our management team and board are sharply focused on the strategies we have set in place while we keep strengthening the important services delivered to our patients, customers, employees, and partners; we value your support and look forward to bringing you an update on our progress. As usual, don't hesitate to get in touch if you have any questions. Thank you, and have a great day.
Operator
operatorThat wraps up our conference. We appreciate you joining the presentation today. You're free to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete American Shared Hospital Services transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to American Shared Hospital Services earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in American Shared Hospital Services or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.